SpringWorks Therapeutics, Inc.

“SpringWorks Therapeutics is committed to developing safe and effective therapies for patients with severe rare diseases and cancer. We believe that, wherever possible, use of an investigational or unlicensed therapy for a patient as part of a clinical trial is preferable because clinical trials are designed to generate comprehensive safety and efficacy data that may lead to the approval of new medicines and, consequently, to wider availability for patients in need. In cases when a patient may not qualify for a clinical trial, there may be no trials available, or a patient has exhausted all available treatment possibilities, SpringWorks may be able to provide access to eligible patients under the supervision of the requesting healthcare provider (HCP) through either our named patient program or our compassionate use program. This refers to the use of a SpringWorks investigational or unlicensed therapy outside of our clinical trials and prior to its commercial availability.”

Your Health Data will be collected in connection with your relationship with SpringWorks when you: 1) engage in a clinical trial that we sponsor; 2) participate in one of our compassionate use programs; 3) provide personal information on our websites and/or marketing programs; and 4) report an adverse event to us.

Conditions: Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Histiocytic Neoplasm, Other MAP-K Pathway Driven Diseases